As I reported some time ago, The aura6000 system consists of an 11 cc rechargeable neurostimulator and a multi-electrode lead that delivers stimulation pulses to the hypoglossal nerve, which controls all muscles of the tongue. Patients use a remote control and charger (RCC) to turn the system on/off and to recharge the neurostimulator.
“We are pleased to have reached this milestone and look forward to making this therapy available to patients at key European centers of excellence in the second half of 2012,” said Marcelo G. Lima, Chairman, President and CEO of ImThera Medical. “This new therapy will prove to be an important tool for physicians to consider for the treatment of OSA.” The limited launch of these systems in Europe represents ImThera Medical’s first commercial efforts.
Company website: www.imtheramedical.com